A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Major Surgery
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2014
Price : $35 *
At a glance
- Drugs Modimelanotide (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 May 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.